About Registration for Biotech/Life Science 2011

• All registrations must be accompanied by payment to be processed.
• Registrations may not be substituted onsite.
• Early registration closes at 5:00pm on Thursday, January 13, 2011.
• Pre-registration closes at 11:59pm on Wednesday, February 16, 2011.
• Due to facility capacity, space is limited, early registration is encouraged.
• Please Note: Your registration will not be process until payment is received.

 

Registration/Cancellation Policy

• Pre-registration closes at 11:59 p.m. on Wednesday, February 16, 2011.
• Cancellations received before January 13, 2011 are refundable less a $50 administrative fee.
• Cancellations received between January 23, 2011 and February 16, 2011 are refundable less 50% of the price at the time of registration.
• Cancellations received after February 16, 2011 are non-refundable.

• Gautam Aggarwal, Senior Practice Executive, Business Development Practice, Campbell Alliance
• Wayne Anderson, Director of Applied Genetics, GlaxoSmithKline
• John A Bilello, Ph.D., Founder and Chief Scientific Officer, Ridge Diagnostics Inc.
• Jeffrey P. Brennan, Senior Vice President, Business and Commercial Development and Chief Business Officer, Targacept, Inc
• Loreen Brown, Vice President, Xcenda
• Todd C. Brady, Ph.D., M.D., Principle, Domain Associates, LLC
• Robert Cascella, President and CEO, Hologic
• Eoin Coakley, Senior Director Clinical Research, Monogram BioSciences
• Deirdre P. Connelly, President, North America Pharmaceuticals, GlaxoSmithKline
• The Honorable Janet Cowell, State Treasurer of North Carolina
• Jeffrey L. Dietz, Director for Alliance Management, Worldwide Business Development, GlaxoSmithKline
• John J. Doyle, Dr.P.H., M.P.H., Managing Director & Practice Leader, Quintiles Consulting
• Steve Ellis, Executive Vice President and Group Head, Wells Fargo Wholesale Services Group
• Eric Faulkner, MPH, Senior Director, Pricing and Reimbursement Market Access and Outcomes Strategy, RTI Health Solutions
• Scott Gottlieb, M.D., Resident Fellow, American Enterprise Institute for Public Policy Research
• The Honorable Kay R. Hagan, United States Senator for North Carolina
• Jennifer Jarrett, Managing Director, CitiBank
• Elaine V. Jones, Ph.D.,Executive Director, Venture Capital & Worldwide Business Development, Pfizer Inc.
• David P. King, Chairman & CEO, LabCorp
• Myla Lai-Goldman, M.D., Managing Partner, Personalized Science, LLC
• Augustine Lawlor, Managing Partner, Healthcare Ventures
• Mark McKinlay, Chief Scientific Officer and Sr. Vice President R&D, TetraLogic Pharmaceuticals
• David Mott, General Partner, NEA (former CEO of MedImmune)
• The Honorable Beverly Eaves Perdue, Governor of North Carolina
• Francis de Rubertis, Partner, Index Ventures
• Mark A. Sirgo, Pharm. D., President and Chief Executive Officer, BioDelivery Sciences International
• Ralph Snyderman, M.D., Chancellor Emeritus and James B. Duke Professor of Medicine, Duke University; Chairman, Proventys, Inc.
• Lawrence Stern, Chairman and CEO, Talecris Biotherapeutics
• Ed Torres, Managing Director, Lilly Ventures
• Jason S. Wood, Partner, Wyrick Robbins Yates & Ponton LLP

 

---

Gautam Aggarwal

Senior Practice Executive, Business Development Practice, Campbell Alliance

Gautam Aggarwal brings several years of experience working within pharmaceutical drug development and management consulting with the pharmaceutical industry to Campbell Alliance’s Business Development Practice.  He has helped define product portfolio strategies, conduct financial valuations, and perform due diligence for clients. Prior to joining Campbell Alliance, Mr. Aggarwal was a Consultant with the Boston Consulting Group.  Prior to that role he worked with GlaxoSmithKline as a Statistician in drug discovery.  Mr. Aggarwal earned an MBA from Duke University’s Fuqua School of Business, and an MS and BS in Biostatistics from the University of North Carolina.

 

Wayne H. Anderson, Ph.D.

Director, Applied Genetics

GlaxoSmithKline
Dr. Anderson earned a Bachelor of Science degree in biology and a Master of Education degree in science education at Springfield College in Springfield, Massachusetts. He then obtained a Doctor of Philosophy degree in pharmacology from the University of South Florida College of Medicine in Tampa, where he also served as a postdoctoral research fellow in the Department of Pharmacology and Therapeutics. Over the past 20 years, Dr. Anderson has held various positions in respiratory clinical research and genetics at GlaxoSmithKline, and is currently Director of Applied Genetics.  In 2000, he was awarded the Glaxo Wellcome Discovery Genetics Award for Innovation in Pharmacogenetics. Before joining the staff of Glaxo, Dr. Anderson was a Research Manager and Group Leader in the Pulmonary Pharmacology Research Division of Ciba-Geigy in Basel, Switzerland, where he won a Ciba research prize for his work on leukotrienes and leukotriene receptor antagonists. He had also held the titles of Senior Scientist and Assistant Research Group Chief in the Department of Pharmacology at Hoffmann-La Roche in Nutley, New Jersey.  He has also held an Adjunct Associate Research Professor in the Department of Medicine, Division of Respiratory Diseases at the University of North Carolina School of Medicine. Dr. Anderson is a member of the American Thoracic Society, and the American Society of Human Genetics and is the Past President and former member of the Board of Directors of the Carolinas Chapter of the Cystic Fibrosis Foundation. He has authored or coauthored more than 40 articles, book chapters, abstracts, and presentations in the field of pharmacogenetics, pharmacology, respiratory disease genetics and cystic fibrosis.

 

[Top]

 

 

John A Bilello, Ph.D.

Founder and Chief Scientific Officer

Ridge Diagnostics Inc.

Dr John A Bilello is a Founder and Chief Scientific Officer of Ridge Diagnostics Inc. Ridge is a biotechology company in Research Triangle Park and San Diego, CA commercializing neuropsychiatric diagnostic tests and developing label-free biomarker detection technology. He received his PhD in Molecular Biology from Albert Einstein College of Medicine in New York. Dr Bilello was a Volkswagen Fellow in the Dept of Molecular Biology at the University of Hamburg in Germany and was an Instructor at the Johns Hopkins Oncology Center in Baltimore, MD. Subsequently he was Chief of the Molecular Biology Laboratory at the VA Medical Center and Associate Professor of Microbiology and Neurology at the University of Maryland School of Medicine. He joined the Division of Clinical Pharmacology at Albany Medical College (New York) where Dr Bilello was Associate Professor of Medicine and Director of the HIV Laboratory. Dr. Bilello later became the Director of Preclinical Research and Development at two successful biotechnology companies SRA Life Sciences and VIRCO Lab USA. In addition to working extensively on HIV drug development in phase I and phase II settings, he also developed technologies used in evaluating preclinical efficacy and in vitro pharmacokinetics and dynamics. As an outgrowth of these research activities he has authored over fifty publications in refereed journals and more than ten book chapters. Prior to being one of the founders of Ridge Diagnostics, Dr Bilello was the Director of Technology Development in Translational Medicine and Genetics at GlaxoSmithKline R&D, with broad responsibility in the discovery and application of human biomarkers. He also provided scientific due diligence for the GSK Technology Investment Board and was an active member of the Disruptive Technological Innovation group, which used future scenario evaluation to provide long-range planning, for technology at GSK. In addition to his activity at Ridge Diagnostics, John is also a Founder and Managing Partner of Innovalyst LLC a life science consulting company based in Research Triangle Park, NC. He is both a current and long-standing member of the editorial board for Antimicrobial Agents and Chemotherapy (1995-2012). In addition to holding current NIH ARRA Catalyst and NSF Phase II SBIR grants, Dr Bilello has been a member of NIH Study Sections and Panels.

 

[Top]

 

 

Todd C. Brady, Ph.D., M.D.

Principle

Domain Associates, LLC

Dr. Brady joined Domain Associates, a leading healthcare venture capital firm, in 2004. Present board memberships include Asmacure, Evoke Pharma, Neuron Systems, Novadigm Therapeutics, ParinGenix, and Sebacia as well as observer status at Carticept Medical, Esperion Therapeutics, IntegenX, and Meritage Pharma. In addition, he is the venture capital advisor to the New Jersey Biotechnology Council Board of Trustees, a member of the Southeast BIO Board of Directors, and a member of the Duke University Graduate School Board of Visitors. Prior to Domain, Dr. Brady was co-founder and CEO of Phenome Sciences, a biotechnology firm he merged with Xanthus Pharmaceuticals (acquired by Antisoma), where he was later Executive Vice President of Strategic Development and Planning. Dr. Brady also worked as head of business development and medical director at Aderis Pharmaceuticals (acquired by Schwarz Pharma, now UCB). While at Xanthus and Aderis, Dr. Brady was a medical consultant on numerous pre-clinical programs and clinical programs in Phases I through IV. Earlier in his career, Dr. Brady was a senior associate at CB Health Ventures (now Excel Medical Ventures), a healthcare venture capital fund.

 

[Top]

 

Senior Vice President, Business and Commercial Development and Chief Business Officer, Targacept, Inc

Jeffrey P. Brennan joined Targacept in September, 2003, and serves as Senior Vice President of Business and Commercial Development and Chief Business Officer. Mr. Brennan has more than 25 years of pharmaceutical industry experience, and has held Executive Management positions at : Sanofi-Synthelabo, Inc., from 1996-2003, and most recently at Targacept.

Throughout his career, Mr. Brennan has demonstrated success in both strategic development and key operations roles. He has developed and expanded the capability and capacity of sales and marketing teams, strategic market research and business analysis divisions, product life cycle management and business development departments. Mr. Brennan received a B.S. in Marketing from Central Connecticut University. He has been a member of the Licensing Executive Society (LES) since 1991 and is a former Board member of the Health Care Committee for the LES. He is currently a member of the American Marketing Association Mr. Brennan has completed over 35 mid- to late-stage business development deals and has been involved in more than 25 product launches in his career. As a member of Sanofi's Executive Management team, he played an instrumental role in helping the company achieve a nearly 10-fold increase in sales, profits, sales force and headquarter expansion over the past six years.

In his role as Targacept's Senior Vice President of Business and Commercial Development and Chief Business Officer, Mr. Brennan is a member of Targacept's Executive Committee and is playing a key role in turning "Science into Business" through key partnerships with AstraZeneca & GlaxoSmithKline.

Loreen M. Brown, MS

Vice President

Xcenda

Loreen M. Brown, MSW, is a Vice President and leads the Access and Reimbursement consulting teams. Ms. Brown leads teams that work wth Xcenda’s pharmaceutical, biotech, and medical device clients in the areas of field support, account management/ training, and reimbursement and health policy research (including strategic planning to address reimbursement, coding, managed care, and government payer challenges). Before joining Xcenda in 2008, Ms. Brown worked for Bayer Healthcare Pharmaceuticals, most recently as the Director of Oncology Customer Marketing. There, she helped design and implement an oral oncolytic distribution and support program during the launch of the Medicare Part D benefit. Ms. Brown has over 10 years of pharmaceutical industry experience primarily focused in the oncology marketplace. Ms. Brown has been an invited speaker at many national conferences and has conducted numerous reimbursement, managed markets, and/or health policy training sessions. She has authored several white papers and articles and is a member of AmerisourceBergen's Health Policy Weekly editorial board. Ms. Brown holds memberships in the Association of Oncology Social Workers, as well as Cambridge Who’s Who. In addition, she earned multiple pharmaceutical awards during her tenure. Ms. Brown received her Bachelor of Science in Biology from the University of Illinois Champaign-Urbana and her Master in Social Work, Policy, Planning, and Administration from The Catholic University of America. She has also worked as a social worker in the public health clinic system in Washington DC and completed a Fellowship in Senator Paul Sarbane’s office, where she concentrated on policies and legislation related to healthcare, specifically Medicare and HIPAA.

 

[Top]

 

 

Robert A. Cascella

President and Chief Executive Officer

Hologic, Inc.
Robert A. Cascella has served as a director of Hologic since June 2008 and as Chief Executive Officer since November 2009. He joined Hologic in February 2003 as Chief Operating Officer and was promoted to President in September 2003. Mr. Cascella has more than 20 years of senior management, operational and finance experience with companies ranging from early-stage, entrepreneurial business to Fortune 500 companies. He joined Hologic from CFG Capital LLC, an investment banking firm specializing in healthcare, where he was a managing partner. Prior to CFG Capital, Mr. Cascella was Chief Operating Officer and Vice President of Finance for NeoVision Corporation, a developer of 3D ultrasound technology used for real-time guidance of interventional breast procedures. Before that, Mr. Cascella was employed at Fischer Imaging Corporation where he held the positions of President, Chief Operating Officer, and Chief Financial Officer. He began his career at Perkin-Elmer in Norwalk, Connecticut. Mr. Cascella received a B.S. in Finance from Fairfield University in 1978.

 

[Top]

 

Eoin Coakley

Senior Director Clinical Research

Monogram BioSciences

Dr Eoin Coakley earned his medical degree from the Royal College of Surgeons in Ireland in 1988. He obtained his Fellowship in Infectious Diseases at the Deaconess Medical Center (subsequently the Beth Israel Deaconess Medical Center) and Harvard Medical School. After graduating from fellowship in 1999 Dr Coakley became a Staff Physician in the Infectious Diseases Division at the Beth Israel Deaconess Medical Center and an Instructor in Medicine at Harvard Medical School. In 2002 Dr Coakley was appointed to Tufts Medical Center as a Staff Physician in the Infectious Diseases Division and an Assistant Professor at Tufts University. Dr Coakley joined Virologic Inc (subsequently Monogram Biosciences) in 2004 where he continues today as Senior Director in Clinical Research. In 2009 Monogram Biosciences was acquired by LabCorp of America. Dr Coakley has more than 20 years experience in the treatment and research of HIV infection. He is a respected expert in the field of HIV Medicine with more than 30 scientific manuscripts in peer reviewed journals and more than 75 presentations at major scientific meetings. At Monogram Biosciences Dr Coakley’s work has focused on HIV drug targets including inhibitors of HIV protease, reverse transcriptase and integrase and HIV maturation and cell entry, providing guidance to the pharmaceutical industry, academics and clinicians as to the activity new antiHIV agents in the clinic and in development. Dr Coakley was a member of the diagnostic-pharmaceutical partnership between Monogram Biosciences and Pfizer Inc. This partnership resulted in the development of the Trofile assay by Monogram Biosciences which was central to the development and approval of Pfizer’s maraviroc, a first in class CCR5 antagonist. The Trofile assay remains the gold standard in the clinic to guide use of this drug and is considered a leading example of a companion diagnostic in the field of personalized medicine. More recently Dr Coakley has focused on innovations to guide drug developmental and treatment of HCV infection.

 

[Top]

 

 

Deirdre P. Connelly

President, North America Pharmaceuticals

GlaxoSmithKline

Deirdre P. Connelly was named President, North America Pharmaceuticals for GlaxoSmithKline in February 2009. She is a member of the global Corporate Executive Team and co-chairs, along with the Chairman, Research and Development, the Portfolio Management Board. Prior to joining GSK, Deirdre spent 26 years with Eli Lilly and Company. She was named president of Lilly USA in June 2005. She held a variety of executive positions, including senior vice president of human resources for Eli Lilly and Company, as well as vice president of human resources for pharmaceutical operations, executive director of global marketing for Evista, and leader of the woman’s health business unit in the U.S. For four consecutive years (2006, 2007, 2008 and 2009), Deirdre was recognized by Fortune magazine as one of the 50 most powerful women in business. In 2008, she was appointed to the President’s Commission on White House Fellowships. In this role, she helps to select the White House Fellows, a prestigious annual program that fosters leadership and public service. Deirdre began her career in the pharmaceutical industry in 1984 as a sales representative for Lilly in San Juan, Puerto Rico. She moved to marketing and then joined their international management development program. Deirdre was named national sales manager for the Puerto Rico affiliate and later became director of sales and marketing for the Caribbean Basin Region. She was also general manager for Eli Lilly Puerto Rico. Born in San Juan, Deirdre earned a bachelor's degree in economics and marketing from Lycoming College in Pennsylvania in 1983. She graduated from Harvard University's Advanced Management Program in 2000. Deirdre serves as a member of the Board of Directors for Macy’s Inc.

 

[Top]

 

 

The Honorable Janet Cowell

State Treasurer of North Carolina

Janet Cowell is the State Treasurer of North Carolina. Elected in 2008, she is the state’s 27th popularly-elected Treasurer and is the first woman to win the post. As the state’s fiscal advisor, Treasurer Cowell oversees more than $67 billion in pension fund investments, affecting 820,000 public employees including teachers, firefighters and other government employees. Cowell and her staff manage the issuance of several billion dollars of debt each year and help cities, towns and counties by monitoring their financial condition while providing professional technical assistance on audit and financial reporting. Her expertise in government operations comes from hands-on experience as a member of the North Carolina Senate and the Raleigh City Council. Cowell is at the forefront of economic development in North Carolina, serving as chair of the State Banking Commission and on the boards of State Education and Community Colleges. An investment professional, Cowell earned an MBA from the Wharton School of Business and a Master’s degree in International Studies from the Lauder Institute. She worked as a financial analyst with HSBC Bank and Lehman Brothers before making her home in North Carolina.

 

[Top]

Jeffrey L. Dietz

Director for Alliance Management, Worldwide Business Development, GlaxoSmithKline

Jeff Dietz joined GSK’s World Wide Business Development department in 2006 as a Director of Alliance Management within R&D and is based in Research Triangle Park.  Having worked in the pharmaceutical industry for over 25 years, Jeff has provided alliance management expertise on a multitude of development and  commercial alliances at GSK to date.  Prior to GSK, Jeff worked for Yamanouchi co-developing and commercializing Vesicare with GSK as a partner, and prior to that worked for Pharmacia in both the US and Canada responsible for  Information Technology, and Business Operations.  

Jeff has a Bachelor of Science degree in Production and Operations from Ohio State University, and is a founding board member of the Association of Strategic Alliance Professionals (ASAP) RTP Chapter.  He also has just recently received his certification as a CSAP - Certified Strategic Alliance Professional. 

 

John J. Doyle, Dr.P.H., M.P.H.

Managing Director & Practice Leader

Quintiles Consulting

Dr. John Doyle leads the U.S. Market Access practice for Quintiles Consulting, focusing on helping life sciences companies maximize the commercial success of their products through market access strategy and evidence-based research. Consulting service areas include pricing and reimbursement strategy, health economic and outcomes research evaluations, health technology assessments, and scenario planning. Previously John served as President of Analytica International, a bio-pharmaceutical consultancy based in New York, NY and Lörrach, Germany specializing in market access strategy. Prior to that, John headed the Oncology and Immunology Economics Research Group at Bristol-Myers Squibb Company. Over the past 15 years, Dr. Doyle has authored over 50 peer-reviewed publications, in a variety of therapeutic areas which a special focus on public health economics. He has consulted global pharmaceutical and biotech firms on strategic concerns regarding product development, pricing, reimbursement, market valuation, launch sequence, and other business issues related to biopharma commercialization. Dr. Doyle is on faculty in the Departments of Epidemiology and Healthcare Policy & Management at Columbia University's Mailman School of Public Health, where he teaches courses in pharmacoeconomics and pharmacoepidemiology. He received a Doctor of Public Health degree and a Master of Public Health degree in Epidemiology from the Mailman School of Public Health at Columbia University. John received a Bachelor of Science degree in Applied Economics with a concentration in the Life Sciences from Cornell University.

 

[Top]

Steve Ellis

Executive Vice President and Group Head

Wells Fargo Wholesale Services Group

Steve Ellis is executive vice president and group head of the Wells Fargo Wholesale Services Group, which includes Enterprise Payment Strategies, Technology Services, and Treasury Management Products and Services. He is responsible for Wholesale Banking operations and support areas including commercial loan services, customer analytics, marketing and communications, risk management, and all activities integrating Wachovia business lines with Wells Fargo Wholesale Banking. Based in San Francisco, he is also a member of the Wells Fargo Management Committee.
The Wholesale Services Group, part of Wholesale Banking, focuses on strengthening and deepening customer relationships by integrating products and services across all channels and businesses, giving customers a consistent experience at all touch points. The 6,800-plus team members sit nationwide, with large concentrations in Charlotte, Denver, Los Angeles, Minneapolis, and San Francisco.
A 23-year company veteran, Steve’s previous responsibilities included starting up and running the Wholesale Internet Solutions group, which launched Wells Fargo’s award-winning Commercial Electronic Office® (CEO®) Internet portal in 2000. The fast pace of Wells Fargo’s early move into online financial services was due in large part to his commitment to fostering workplace creativity.
Prior to starting up Wholesale Internet Solutions, Steve held senior finance and operations roles in Wells Fargo Commercial Banking, Real Estate Group, and Wholesale Banking.
He has a B.S. in economics from Pennsylvania State University and an M.B.A. from the University of Oregon.
Steve serves on the Wells Fargo Environmental Affairs Council. He served as Chairman of the Board from 2005 to 2008 and Vice Chairman from 2009 to 2010 for NACHA, The Electronic Payments Association.

 

 

Eric Faulkner MPH

Senior Director, Pricing and Reimbursement Market Access and Outcomes Strategy

RTI Health Solutions

Eric C. Faulkner, MPH, is Senior Director of US Market Access and Reimbursement at RTI HS. He has approximately 15 years of experience focusing on health technology assessment, product reimbursement and commercialization, health care management, and health policy analysis. He has broad therapeutic experience, including in NSCLC. Mr. Faulkner has recently served as an expert advisor to the Personalized Medicine Subcommittee of the President’s Council of Advisors on Science and Technology and the Personalized Healthcare Initiative of the US Department of Health and Human Services. He is serving as the Chair of the Personalized Medicine Special Interest Group of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) and on the Leadership Committee of the Health Technology Assessment Special Interest Group of ISPOR, including working groups on both drugs and medical devices and diagnostics. Eric is also a member of the Leadership Committee of the Business Models and Reimbursement Working Group of the International Society for Cellular Therapy (ISCT). Eric has significant experience in evidence-based practice and policy. He has served as a project manager for the AHRQ Evidence-Based Practice Center program and US Preventive Services Task Force (USPSTF) initiatives. Eric has managed multiple public and commercial health technology assessments of drugs, medical devices, and diagnostics. He has also led health policy assessments, including CMS’s Coverage with Evidence Development (CED) and Clinical Trial Policy, value-based purchasing, competitive bidding, cost-effectiveness, comparative effectiveness, pharmacogenomics, and health care transparency for life sciences manufacturers, industry and medical professional associations, and government agencies, including HHS, NIH, FDA, CDC, and ASPE. Prior to joining RTI-HS, Mr. Faulkner was a senior consultant at the Littell Group and The Lewin Group. In these positions, he managed a portfolio of consulting projects, including reimbursement strategy analysis, design of clinical trials to meet requirements of third-party health decision makers, life sciences stakeholder surveys, burden of illness studies, and analysis of key health policy initiatives. In previous positions, he provided intellectual property consulting services and managed a variety of genomic and molecular research initiatives for the NIH and Duke University. Eric is often sought after as an expert working/advisory group member and speaker on topics relevant to emerging technology adoption and diffusion and currently serves as the Executive Director of the Genomics Biotech Institute of the National Association of Managed Care Physicians and Editor-in-Chief of the GBI special section of the Journal of Managed Care Medicine. Eric also serves as an adjunct Assistant Professor for the Institute for Pharmacogenomics and Individualized Therapy at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill and on the Advisory Board of the Center for Translational and Policy Research on Personalized Medicine of the University of San Francisco at California. University of North Carolina, Chapel Hill, NC BS, Biology Radford University, Radford, VA

 

[Top]